Adolor to Host Investor Conference Call to Discuss the FDA Approval of Entereg(R) (alvimopan)
May 20 2008 - 5:44PM
Business Wire
Adolor Corporation (NASDAQ:ADLR) will be hosting an investor
conference call and webcast on Wednesday, May 21, 2008 at 8:30 a.m.
Eastern Time to discuss the U.S. Food and Drug Administration (FDA)
approval of Entereg� (alvimopan) capsules to help patients regain
gastrointestinal function earlier following bowel resection
surgery. To participate in the audio portion and have the
opportunity to pose questions, dial 1-877-726-1721 for domestic
callers and 1-706-902-2930 for international callers and enter
Conference ID #48212826. An audio webcast also will be available on
the Investor Relations section of Adolor's website, www.adolor.com.
A replay of the conference call will be available beginning at
10:00 a.m. Eastern Time on May 21, 2008. To listen to a replay of
the conference call, dial 1-800-642-1687 (domestic callers) or
1-706-645-9291 (international callers) and enter Conference ID
#48212826 or listen via Adolor's website. The replay will be
available for one week. About Adolor Corporation Adolor Corporation
(Nasdaq:ADLR) is a biopharmaceutical company specializing in the
discovery, development and commercialization of novel prescription
pain management products. By applying its knowledge and expertise
in pain management, along with ingenuity, Adolor is seeking to make
a positive difference for patients, caregivers and the medical
community. For more information, visit www.adolor.com. Adolor
Forward-Looking Statements This release, and oral statements made
with respect to information contained in this release, may
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those which express plan,
anticipation, intent, contingency, goals, targets or future
development and/or otherwise are not statements of historical fact.
These statements are based upon management's current expectations
and are subject to risks and uncertainties, known and unknown,
which could cause actual results and developments to differ
materially from those expressed or implied in such statements. Such
known risks and uncertainties relate to, among other factors: the
risk that Entereg may not be a commercial success; the uncertainty
of market acceptance of Entereg, including acceptance by hospitals,
physicians, payors or the medical community; the risk that the Risk
Evaluation and Mitigation Strategy or REMS, including the
registration of hospitals could materially adversely affect the
commercial prospects for ENTEREG or negatively impact the uptake of
Entereg, the risks associated with government regulations relating
to marketing and selling pharmaceutical products; the risk of
product liability claims; the risks of reliance on third party
manufacturers; the risk of competitive products; the risk that the
alvimopan Investigational New Drug Application (IND) for OBD
remains on clinical hold indefinitely; the risk that Entereg may
not be approved in OBD or any indication other than the FDA
approved indication in bowel resection surgery; the risk that
filing targets for regulatory submissions are not met; the risk
that the results of other clinical trials of Adolor's drug products
and drug product candidates, including ENTEREG, are not positive or
do not support safety or efficacy; the costs, delays and
uncertainties inherent in scientific research, drug development,
clinical trials and the regulatory approval process; the changing
regulatory environment; risks associated with intellectual property
protection for Adolor�s products and third party intellectual
property; Adolor's history of operating losses since inception and
its need for additional funds to operate its business; Adolor's
reliance on its collaborators, including GSK, in connection with
the development and commercialization of ENTEREG; market acceptance
of Adolor's products, if regulatory approval is achieved;
competition; and securities litigation. Further information about
these and other relevant risks and uncertainties may be found in
Adolor's Reports on Form 8-K, 10-Q and 10-K filed with the U.S.
Securities and Exchange Commission. Adolor urges you to carefully
review and consider the disclosures found in its filings which are
available in the SEC EDGAR database at http://www.sec.gov and from
Adolor at http://www.adolor.com. Given the uncertainties affecting
pharmaceutical companies in the development stage, you are
cautioned not to place undue reliance on any such forward-looking
statements, any of which may turn out to be wrong due to inaccurate
assumptions, unknown risks, uncertainties or other factors. Adolor
undertakes no obligation to (and expressly disclaims any such
obligation to) publicly update or revise the statements made herein
or the risk factors that may relate thereto whether as a result of
new information, future events, or otherwise.
Adolor Corp. (MM) (NASDAQ:ADLR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adolor Corp. (MM) (NASDAQ:ADLR)
Historical Stock Chart
From Jul 2023 to Jul 2024